Keloid

Clinical Comprehensive Guide: Keloid Pathophysiology and Management

1. Comprehensive Introduction & Overview

A keloid is a pathological fibroproliferative disorder characterized by the excessive deposition of collagen within the dermis and subcutaneous tissues following cutaneous injury. Unlike hypertrophic scars, which remain confined to the boundaries of the original wound and may regress over time, keloids are defined by their propensity to extend beyond the original site of injury (pseudotumor growth) and their failure to regress spontaneously.

From a clinical perspective, keloids represent a failure in the wound-healing regulatory mechanisms. They are essentially benign fibroproliferative growths that can cause significant physical discomfort, psychological distress, and functional impairment. While they are not inherently malignant, their cosmetic impact and the chronic symptoms they produce—such as pruritus, pain, and paresthesia—necessitate a sophisticated clinical approach to management.

2. Deep-Dive: Mechanisms and Pathophysiology

The pathophysiology of keloids is complex, involving a dysregulated interplay between inflammatory cells, fibroblasts, and the extracellular matrix (ECM).

The Cellular Mechanism

• Fibroblast Hyperactivity: Keloid-derived fibroblasts (KFs) exhibit an enhanced proliferative rate and a significantly elevated expression of collagen types I and III.
• Dysregulated Apoptosis: Unlike normal fibroblasts, KFs demonstrate resistance to apoptosis, leading to an accumulation of collagenous material.
• Cytokine Signaling: There is an overexpression of transforming growth factor-beta (TGF-β1 and TGF-β2), which acts as a potent stimulator of collagen synthesis.
• Hypoxia-Inducible Factors (HIFs): Local hypoxia in the wound environment triggers HIF-1α, which promotes neoangiogenesis and collagen deposition via vascular endothelial growth factor (VEGF).

Genetic Predisposition

Keloids show a clear genetic component, often exhibiting autosomal dominant inheritance with incomplete penetrance. Genetic studies have identified specific loci on chromosomes 2q23 and 15q21 that correlate with increased susceptibility. Ethnic background is a significant risk factor; individuals of African, Asian, and Hispanic descent are disproportionately affected, with prevalence rates significantly higher than in Caucasian populations.

3. Clinical Indications, Staging, and Presentation

Standard Presentation

Keloids typically present as firm, rubbery, or hard lesions with a smooth, shiny surface. They are often raised above the skin level and may appear erythematous, hyperpigmented, or hypopigmented depending on the patient's Fitzpatrick skin type.

Clinical Staging (The Vancouver Scar Scale Modification)

While no singular global staging system exists, clinicians often categorize keloids by size and functional impact:
1. Stage I (Minor): Small, localized, usually on the earlobe; easily treated with intralesional steroids.
2. Stage II (Moderate): Larger, multi-lobular, extending to adjacent tissue; requires multimodal intervention.
3. Stage III (Severe/Giant): Massive, deforming, causing contractures; often requires surgical excision followed by adjuvant radiotherapy.

4. Differential Diagnosis and Diagnostic Testing

It is imperative to distinguish a keloid from other fibroproliferative conditions to ensure appropriate treatment.

Differential Diagnosis Table

Diagnostic Gold Standards

• Clinical Examination: In most cases, the diagnosis is clinical. The hallmark of "growth beyond the wound margin" is diagnostic.
• Punch Biopsy: Reserved for cases where the diagnosis is unclear or malignancy is suspected (e.g., rapid, atypical growth). Histopathology reveals thick, glassy, eosinophilic collagen bundles in a haphazard arrangement.
• Dermoscopy: Useful to visualize vascular patterns; keloids often show arborizing vessels, whereas malignancies show more chaotic vascularity.

5. Risks, Side Effects, and Contraindications

Treating keloids is notoriously difficult due to a high recurrence rate, which can reach 50–80% if surgical excision is performed as a monotherapy.

Risks of Intervention

• Surgical Excision: High risk of recurrence; often the keloid returns larger than the original lesion.
• Intralesional Corticosteroids (Triamcinolone): Can lead to skin atrophy, hypopigmentation, and telangiectasia.
• Cryotherapy: Risk of permanent pigmentary changes (hypopigmentation) and nerve damage in thin-skinned areas.
• Radiotherapy (Adjuvant): Minimal risk of radiation-induced malignancy, though this is statistically very low with modern protocols.

Contraindications

• Active Infection: Treating an inflamed or infected keloid can lead to abscess formation.
• Unrealistic Expectations: Patients must be counseled that keloids are chronic conditions; "cure" is rarely 100% achievable in the cosmetic sense.

6. Massive FAQ Section

Q1: Are keloids cancerous?

No, keloids are benign fibroproliferative growths. They do not metastasize and are not a form of skin cancer.

Q2: Why do keloids return after surgery?

Surgical excision removes the bulk of the tissue but does not correct the underlying genetic and molecular dysregulation (the "keloid diathesis"). Without adjuvant therapy, the wound-healing process repeats the same error.

Q3: Can keloids be prevented?

For high-risk individuals, avoiding elective cosmetic surgery, piercings, and tattoos is the best prevention. If surgery is necessary, tension-free closure and post-operative pressure garments are recommended.

Q4: Is there a specific diet for keloids?

There is no clinical evidence that diet affects keloid formation, though maintaining overall skin health and controlling systemic inflammation may have theoretical benefits.

Q5: What is the role of pressure therapy?

Pressure therapy (silicone sheeting or custom garments) is considered a first-line prophylactic measure. It works by inducing local ischemia and decreasing fibroblast activity.

Q6: How long does a keloid grow?

Keloids can grow for months or even years. Some reach a "plateau" phase where they stop expanding, while others continue to enlarge slowly over a lifetime.

Q7: Are injections painful?

Intralesional steroid injections can be painful due to the density of the keloid tissue. Many clinicians use a topical anesthetic or cryo-anesthesia to mitigate discomfort.

Q8: Does laser treatment work?

Pulsed-dye lasers (PDL) are effective at reducing the vascularity and redness of keloids and can improve texture, but they are rarely effective as a monotherapy for large lesions.

Q9: Can I get a keloid from a vaccine?

Yes, keloids have been reported at the site of vaccinations, particularly the BCG vaccine, due to the inflammatory nature of the injection.

Q10: What is the current "gold standard" for treatment?

The current consensus for severe keloids is multimodal therapy: surgical excision followed immediately by adjuvant radiotherapy (or intralesional corticosteroids/5-fluorouracil) to suppress fibroblast proliferation during the re-epithelialization phase.

7. Long-term Prognosis and Management Strategy

The prognosis for a patient with keloids depends heavily on the consistency of the treatment regimen and the patient's adherence to long-term follow-up.

Long-term Management Protocol:

1. Phase 1 (Active): Debulking via surgery or intralesional therapy (Steroids + 5-FU).
2. Phase 2 (Suppression): Immediate application of pressure therapy or silicone gel sheets for 6–12 months.
3. Phase 3 (Maintenance): Regular clinical monitoring every 3 months for the first year to detect early signs of recurrence.

Clinicians must emphasize that keloid management is a marathon, not a sprint. Patients should be educated on the importance of avoiding trauma to the site and the early reporting of any new symptoms, such as increased pruritus or rapid expansion, which may signal a recurrence. By combining surgical precision with aggressive adjuvant medical management, the majority of patients can achieve significant aesthetic and symptomatic improvement.